Benecard and DecisionRX Formed a Partnership to Enhance Pharmacy Benefits Announcement DecisionRX, Inc., a key player in medication therapy optimization (MTO), and Benecard PBF, the original pharmacy benefit facilitator (PBF), entered into a strategic partnership initiated to introduce persona...
Kedrion’s COAGADEX® Received Confirmation of ‘Orphan Drug Designation' Announcement Kedrion Biopharma’s COAGADEX is now declared an orphan drug designation from the US Food and Drug Administration (FDA). The coagulation factor X human (tradename COAGADEX) will be a treatm...
Genethon's New Trial in Europe for Duchenne Muscular Dystrophy Announcement Genethon, a global prominent leader in research and development in gene therapy for rare genetic diseases, received approval from regulatory authorities, EMA and MHRA, for crucial phase 3 clinical trials in the UK and ...
Bristol and Bain Capital’s New Company Announcement Bristol-Myers Squibb and Bain Capital together have built a new independent biopharmaceutical company. A company that will be aiming the develop new treatments for autoimmune diseases that address the prominent needs of patients. The ne...
Pahr Therapeutics Raises Funds to Contribute to Pulmonary Arterial Hypertension Announcement Pahr Therapeutics Inc. was financed with $14M, along with AN Venture partners, University of Tokyo Edge Capital Partners (UTEC), and RA Capital Management. The company tends to develop therapies for pu...
Virocell and Avencell Partnered to Elevate Development in Treatments Announcement Virocell biologics, a popular vector contract development and manufacturing organization (CDMO) for cell and gene therapy (CGT) clinical trials, entered a partnership with Avencell Therapeutics Inc., a global cli...
Spear Bio’s New Solution to Modify Neurodegenerative Disease Research Announcement Spear Bio, a leading biotechnology company evolving homogeneous ultrasensitive immunoassay technology, has now commercially introduced SPEAR Ultradetect™ immunoassay solution. The new solution provid...
The Rising Alzheimer's Disease has Led Biopharma to Enter a Holistic Treatment Era The start to look up for In the last two years, 2023 and 2024, the treatment for the first-ever disease, Alzheimer's, received approval, which was introduced by Eisai and Biogen (for Leqembi) and Eli Lilly&rsquo...
GSK and Hengrui Pharma’s Collaboration for Drug Development Announcement Hengrui Pharma signed an agreement with GSK plc to develop 12 innovative medicines in addition to Hengrui’s primary value to the effective globalized strategy and GSK's new growth opportunities through 2031. T...
The New FDA Vouchers and Drug Pricing Confusion, a New Chaos in the Biopharma Sector FDA’s New Voucher Program or Confusion The commissioner's national priority vouchers focus on providing elevated pathways for drugs similar to few criteria, including a low price tag. This policy was exp...
